These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16210092)

  • 1. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Claus R; Almstedt M; Lübbert M
    Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
    Rüter B; Wijermans PW; Lübbert M
    Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
    Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
    Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW; Jabbour E; Kantarjian HM; Giles FJ
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demethylation of DNA by decitabine in cancer chemotherapy.
    Brown R; Plumb JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):501-10. PubMed ID: 15270655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS
    Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.
    Nagasawa T; Zhang Q; Raghunath PN; Wong HY; El-Salem M; Szallasi A; Marzec M; Gimotty P; Rook AH; Vonderheid EC; Odum N; Wasik MA
    Leuk Res; 2006 Mar; 30(3):303-12. PubMed ID: 16185764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
    Lakshmikuttyamma A; Scott SA; DeCoteau JF; Geyer CR
    Oncogene; 2010 Jan; 29(4):576-88. PubMed ID: 19881540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
    Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
    Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
    Murgo AJ
    Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
    Shin H; Kim JH; Lee YS; Lee YC
    Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.